Redx Pharma plc Poster Presentation at AACR Annual Meeting
March 15 2018 - 2:01AM
RNS Non-Regulatory
TIDMREDX
Redx Pharma plc
15 March 2018
REDX PHARMA PLC
("Redx" or "the Company")
Redx Pharma to present poster at prestigious American
Association for Cancer Research Annual Meeting
Poster shows that lead candidate, RXC004 - a selective, orally
bioavailable porcupine inhibitor- enhances immune response in
pre-clinical models of cancer
Dosing recently commenced in phase 1/2a clinical trial of RXC004
in patients with hard to treat cancers
Alderley Park, March 15 2018 - Redx Pharma (AIM: REDX), the drug
discovery and development company focused on cancer and fibrosis,
announces that the Company's submitted abstract has been accepted
for presentation as a poster at the American Association for Cancer
Research (AACR) Annual Meeting in Chicago, 14-18 April 2018.
The poster relates to the Company's lead candidate, RXC004, a
potent and selective, orally bioavailable porcupine (PORCN)
inhibitor, which is currently being investigated in a phase 1/2a
clinical trial in patients with hard to treat cancers. It is
expected that initial data from the 1a segment of this trial will
be available in H2 2018.
Richard Armer, Chief Scientific Officer of Redx Pharma plc,
commented, "We are delighted that our abstract has been accepted at
such a high profile conference. We are excited by the potential of
RXC004 as a treatment for challenging cancers and look forward to
announcing the first data from our clinical development programme
with this compound."
The abstract will be presented as a poster on 17 April 2018
8.00am - 12.00pm CST, further details below:
Session Category: Immunology
Session Title: Immunomodulatory Agents and Interventions 1
Abstract Title: Porcupine inhibitor RXC004 enhances immune
response in pre-clinical models of cancer
Location: McCormick Place South, Exhibit Hall A, Poster Section
32
Poster Board Number: 14
Permanent Abstract Number: 3764
First author: Inder Bhamra
For further information, please contact:
Redx Pharma Plc T: +44 1625
469 918
Iain Ross, Executive Chairman
Cantor Fitzgerald Europe (Nominated T: +44 20
Advisor & Broker) 7894 7000
Phil Davies
WG Partners LLP (Joint Broker) T: +44 20
3705 9330
Claes Spång/ Chris Lee/ David
Wilson
FTI Consulting T: +44 20
3727 1000
Simon Conway/Stephanie Cuthbert
About Redx Pharma Plc
Redx is a UK biotechnology company whose shares are traded on
AIM (AIM:REDX). Redx is focused on creating and developing first,
or potentially best in class drugs, in specific areas of cancer and
fibrosis that address significant unmet medical need. Redx has an
in-house discovery team with proven world-class chemistry
capabilities.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAKMGMFVDMGRZM
(END) Dow Jones Newswires
March 15, 2018 03:01 ET (07:01 GMT)
Redx Pharma (LSE:REDX)
Historical Stock Chart
From Apr 2024 to May 2024
Redx Pharma (LSE:REDX)
Historical Stock Chart
From May 2023 to May 2024